NASDAQ:MCRB

1.10
0.02 (1.85%) 1d
0
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Based on the reviews from different experts, it is evident that Seres Therapeutics (MCRB-Q) is poorly run and is experiencing substantial financial losses. This indicates a lack of effective management and financial stability, which could affect the company's long-term viability. Investors should approach this stock with caution and conduct thorough research before considering any investment.

Consensus
Negative
Valuation
Overvalued
DON'T BUY
Seres Therapeutics

Poorly run, and it's losing money hand over fist.

biotechnology / pharmaceutical
Showing 1 to 1 of 1 entries
  • «
  • 1
  • »

Seres Therapeutics(MCRB-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Seres Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Seres Therapeutics(MCRB-Q) Frequently Asked Questions

What is Seres Therapeutics stock symbol?

Seres Therapeutics is a American stock, trading under the symbol MCRB-Q on the NASDAQ (MCRB). It is usually referred to as NASDAQ:MCRB or MCRB-Q

Is Seres Therapeutics a buy or a sell?

In the last year, 1 stock analyst published opinions about MCRB-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Seres Therapeutics.

Is Seres Therapeutics a good investment or a top pick?

Seres Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Seres Therapeutics.

Why is Seres Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Seres Therapeutics worth watching?

In the last year 1 stock analyst on Stockchase covered Seres Therapeutics. The stock is worth watching.

What is Seres Therapeutics stock price?

On 2024-05-02, Seres Therapeutics (MCRB-Q) stock closed at a price of $1.1.